Ignite Creation Date:
2025-12-24 @ 5:19 PM
Ignite Modification Date:
2026-02-20 @ 4:49 PM
Study NCT ID:
NCT05502250
Status:
RECRUITING
Last Update Posted:
2024-08-19
First Post:
2022-05-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission
Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-14
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-04
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-25
First Submit QC Date:
None
Study First Post Date:
2022-08-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-16
Last Update Post Date:
2024-08-19
Last Update Post Date Type:
ACTUAL